RPG Life Sciences Targets Bigger API Expansion After ₹215 Crore Acquisitions; GLP-1 Launch in October

The Quick Take

• RPG Life Sciences spent ₹215 crore acquiring Actis Generics and Raghava Life Sciences in five weeks, boosting API capacity fivefold to 505 KL.
• The company will launch a GLP-1 drug in October as it expands into the high-growth diabetes and weight management market.
• RPG plans to deploy a further ₹500-700 crore in acquisitions and organic expansion over the next 12 months.

RPG Life Sciences has executed an aggressive M&A sprint, deploying ₹215 crore across two acquisitions—Actis Generics and Raghava Life Sciences—in just five weeks, expanding its API manufacturing capacity nearly fivefold from a lower base to 505 KL. This rapid capacity buildup positions the company for a GLP-1 drug launch in October 2026, entering one of pharma's highest-growth therapeutic categories. The acquisitions also expanded the company's customer base from under 100 to more than 250, broadening its revenue distribution across global markets.

RPG's October GLP-1 launch and API capacity expansion puts it in direct competition with a wave of Indian pharma companies targeting the rapidly growing diabetes and obesity treatment market, where Novo Nordisk's Ozempic and Eli Lilly's Mounjaro have created unprecedented global demand for GLP-1 analogues. The company's workforce expansion from 217 to over 500 employees reflects the operational scale required to service this broader API portfolio, with regulatory capabilities strengthened through the acquisition of established manufacturing entities.

Watch RPG Life Sciences' GLP-1 product launch performance in the October quarter and whether its 250+ customer base translates to sustained order flow for the acquired API facilities. The macro variable is the global generic GLP-1 API market's evolution: if Novo Nordisk and Eli Lilly maintain exclusivity for longer than expected, the Indian API supplier window for branded GLP-1 production shifts, while any patent cliff acceleration would rapidly expand RPG's addressable market.

Synthesized from 3 sources.